ArticleInternational journal of clinical oncology2025
Prognostic impact of dose reduced S-1 adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: a retrospective multicenter study.
Article in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Higher lymph node burden predicts greater chemotherapy benefit in resected pancreatic ductal adenocarcinoma: evidence from 22,045 patients.Scientific reports · 2026Article
- Perioperative Nutritional Changes Predict Adjuvant S-1 Dose Intensity in Resectable Pancreatic Cancer.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe standard adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDAC) in Japan is S-1; however, the impact of dose reduction on prognosis remains unclear. We have reported that total dose intensity (TDI) ≥ 62.5% indicates good prognosis. This multicenter retrospective study evaluated the prognostic impact of TDI ≥ 62.5% and reduced dosing in patients who underwent radical resection for PDAC across three institutions.
methodPatients were grouped into high-TDI (≥ 62.5%) and low-TDI (< 62.5%) based on this cutoff. We performed an inverse probability of treatment weighting (IPTW)-adjusted analysis and calculated relapse-free survival (RFS) and overall survival (OS). OS was also calculated for high TDI with TDI < 100% and TDI = 100%.
resultAmong 487 patients, 274 were included: 152 in the low-TDI and 122 in high-TDI groups. Patient background was adjusted using IPTW based on factors that might influence TDI. The median RFS for low- and high-TDI was 8 and 18 months, respectively (p = 0.004). The median OS of low- and high-TDI groups was 20 and 50 months, respectively (p < 0.001). Among patients with high TDI, OS did not differ between those with TDI < 100% and those with TDI = 100% (median, 47 vs. 72 months, p = 0.208).
conclusionIt has been suggested that a partial dose reduction of S-1 as adjuvant chemotherapy for PDAC does not significantly impact prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.